Balistreri Carmela Rita, Magro Daniele, Scola Letizia, Aridon Paolo, Ragonese Paolo, Dos Santos Mendes Felipe Augusto, Schirò Giuseppe, D'Amelio Marco
Cellular, Molecular and Clinical Pathological Laboratory, Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), University of Palermo, 90134 Palermo, Italy.
Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.
Int J Mol Sci. 2025 May 8;26(10):4503. doi: 10.3390/ijms26104503.
Currently, the management of Parkinson's disease (PD), the second most common neurodegenerative disease, is challenging due to the lack of consensus on blood biomarkers for diagnostic, prognostic, and outcome purposes. The identification of specific and sensitive biomarkers could contribute to an early diagnosis and, consequently, facilitate management and improve prognosis. Several molecules are emerging as potential biomarkers, although current data seem preliminary and need further validation. Further, their combination in a panel seems to strengthen their diagnostic power, allowing them to identify PD cases with greater specificity and sensitivity. In this study, we evaluated the association of a panel of molecules, including shed syndecans, ELA peptides, CD141, VEGF, BDNF, and systemic inflammatory indices, in 30 PD cases and 30 matched healthy controls. Significant differences in the systemic levels of all the molecules studied were detected in the PD group when compared to the healthy participants. Univariate and multivariate regression analyses, as well as correlations with clinical indicators, including PD severity expressed by the Hoehn and Yahr (H&Y) scale, highlighted the key role of the studied molecules as independent risk factors. Finally, the use of receiver operating characteristic (ROC) curves demonstrated the diagnostic value of hs-CRP, NLR, BDNF, shed syndecans (1-3), and ELA-32 in PD. Interestingly, their diagnostic performance significantly improved when combined in a panel. Overall, our results suggest that hs-CRP, NLR, BDNF, shed syndecans (1-3), and ELA-32 are significantly associated with PD and could likely serve as appropriate diagnostic and prognostic biomarkers, especially if combined in a panel.
目前，帕金森病（PD）作为第二常见的神经退行性疾病，其管理颇具挑战性，因为在用于诊断、预后和评估结果的血液生物标志物方面缺乏共识。识别特异性和敏感性高的生物标志物有助于早期诊断，进而便于管理并改善预后。尽管目前的数据似乎尚属初步且需要进一步验证，但已有几种分子正在成为潜在的生物标志物。此外，将它们组合成一个指标组似乎能增强其诊断能力，使其能够更具特异性和敏感性地识别帕金森病病例。在本研究中，我们评估了一个分子指标组的关联性，该指标组包括脱落的 Syndecans、ELA 肽、CD141、血管内皮生长因子（VEGF）、脑源性神经营养因子（BDNF）以及全身炎症指标，研究对象为 30 例帕金森病患者和 30 例匹配的健康对照者。与健康参与者相比，帕金森病组中所有研究分子的全身水平均存在显著差异。单变量和多变量回归分析以及与临床指标的相关性分析，包括用 Hoehn 和 Yahr（H&Y）量表表示的帕金森病严重程度，均突出了所研究分子作为独立危险因素的关键作用。最后，通过绘制受试者工作特征（ROC）曲线证明了高敏 C 反应蛋白（hs-CRP）、中性粒细胞与淋巴细胞比值（NLR）、脑源性神经营养因子（BDNF）、脱落的 Syndecans（1 - 3）和 ELA - 32 在帕金森病中的诊断价值。有趣的是，当它们组合成一个指标组时，其诊断性能显著提高。总体而言，我们的结果表明，hs-CRP、NLR、BDNF、脱落的 Syndecans（1 - 3）和 ELA - 32 与帕金森病显著相关，并且很可能作为合适的诊断和预后生物标志物，尤其是在组合成一个指标组时。
